Orthocell Submits Application to the British Standards Institution for Approval for Commercial Distribution of Nerve Repair Product, Shares Up 3%

MT Newswires Live12-15

Orthocell (ASX:OCC) submitted a regulatory application to the British Standards Institution for approval to commercially distribute its nerve repair product Remplir into the European Union and UK markets, according to a Monday Australian bourse filing.

The regulatory approval for the required European Conformity (EC) and UK Conformity Assessed (UKCA) certifications is expected to be received in the September quarter of 2026.

Its shares rose 3% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment